Overview
This study was to explore the effectiveness and safety of early TMZ chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen.
Description
This study was to explore the effectiveness and safety of early temozolomide chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen. Patients were treated with a standard therapy regimen (Stupp) plus early postsurgical temozolomide.
Eligibility
Inclusion Criteria:
Age: 18 years to 70 years; Newly diagnosed Glioblastoma in the supratentorial cerebral
hemisphere; Gross total resection or large resection of >70% in imaging studies; Eastern
Cooperative Oncology Group performance status of 0-2; Adequate bone marrow, liver and renal
function; Ability of subject to understand character and individual consequences of the
clinical trial Written informed consent; anticipating survival ≥7 months.
Exclusion Criteria:
Refusal to participate the study; Current diagnosis or history of malignancies within the
3-year period preceding enrollment; Recurrent or multiple malignant gliomas, including
gliomatosis cerebri, or metastatic extracalvarial or subtentorial lesions; Known
hypersensitivity or contraindication to temozolomide; Pregnant or lactating females;
Malignant tumor other than brain tumor; Contraindicated for MRI examination; Unable to
comply with the follow-up studies of this trial; Uncontrolled psychotic disorders or
epilepsy.